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Abstract
BACKGROUND—Combination antiplatelet therapy with clopidogrel and aspirin may reduce the 
rate of recurrent stroke during the first 3 months after a minor ischemic stroke or transient 
ischemic attack (TIA). A trial of combination antiplatelet therapy in a Chinese population has 
shown a reduction in the risk of recurrent stroke. We tested this combination in an international 
population.
METHODS—In a randomized trial, we assigned patients with minor ischemic stroke or high-risk 
TIA to receive either clopidogrel at a loading dose of 600 mg on day 1, followed by 75 mg per 
day, plus aspirin (at a dose of 50 to 325 mg per day) or the same range of doses of aspirin alone. 
The dose of aspirin in each group was selected by the site investigator. The primary efficacy 
outcome in a time-to-event analysis was the risk of a composite of major ischemic events, which 
was defined as ischemic stroke, myocardial infarction, or death from an ischemic vascular event, at 
90 days.
RESULTS—A total of 4881 patients were enrolled at 269 international sites. The trial was halted 
after 84% of the anticipated number of patients had been enrolled because the data and safety 
monitoring board had determined that the combination of clopidogrel and aspirin was associated 
with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin 
alone at 90 days. Major ischemic events occurred in 121 of 2432 patients (5.0%) receiving 
clopidogrel plus aspirin and in 160 of 2449 patients (6.5%) receiving aspirin plus placebo (hazard 
ratio, 0.75; 95% confidence interval [CI], 0.59 to 0.95; P = 0.02), with most events occurring 
during the first week after the initial event. Major hemorrhage occurred in 23 patients (0.9%) 
*A complete list of the POINT Investigators is provided in the Supplementary Appendix, available at NEJM.org.
Address reprint requests to Dr. Johnston at Dell Medical School, University of Texas at Austin, 1501 Red River St., Austin, TX 78701, 
or at clay.johnston@utexas.edu. 
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
HHS Public Access
Author manuscript
N Engl J Med. Author manuscript; available in PMC 2019 January 19.
Published in final edited form as:













receiving clopidogrel plus aspirin and in 10 patients (0.4%) receiving aspirin plus placebo (hazard 
ratio, 2.32; 95% CI, 1.10 to 4.87; P = 0.02).
CONCLUSIONS—In patients with minor ischemic stroke or high-risk TIA, those who received a 
combination of clopidogrel and aspirin had a lower risk of major ischemic events but a higher risk 
of major hemorrhage at 90 days than those who received aspirin alone. (Funded by the National 
Institute of Neurological Disorders and Stroke; POINT ClinicalTrials.gov number, 
NCT00991029.)
The risk of ischemic stroke ranges from 3 to 15% in the 90 days after a minor ischemic 
stroke or a transient ischemic attack (TIA).1–5 In several trials, aspirin has been shown to 
reduce the risk of recurrent stroke by approximately 20%.6–10 Clopidogrel blocks platelet 
aggregation through the P2Y12-receptor pathway, a mechanism that is synergistic with 
aspirin in platelet-aggregation assays. The combination of the two drugs has been more 
effective than aspirin alone in reducing the risk of ischemic events in patients with acute 
coronary syndromes.11
We conducted the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke 
(POINT) trial to evaluate clopidogrel plus aspirin, as compared with aspirin alone, in an 
international population of patients who had a minor ischemic stroke or TIA. The 
Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events 
(CHANCE) trial, which was initiated after the POINT trial and was completed before the 
termination of the POINT trial, showed a 32% lower risk of stroke recurrence among 
Chinese patients who were treated within 24 hours after a minor ischemic stroke or TIA with 
a combination of clopidogrel and aspirin than among those who were treated with aspirin 
alone, with no increase in the risk of hemorrhagic complications.12 The restricted ethnic 
population and patterns of care in that trial limited the generalizability of the results, and the 
combination of clopidogrel and aspirin has not been recommended routinely in guidelines 
for the treatment of stroke.6,10
METHODS
TRIAL DESIGNS AND OVERSIGHT
We enrolled patients in this randomized, double-blind, placebo-controlled trial from May 28, 
2010, to December 19, 2017, at 269 sites in 10 countries in North America, Europe, 
Australia, and New Zealand, with the majority of the patients (82.8%) enrolled in the United 
States. The trial was approved by the ethics committee at each participating site. The trial 
protocol is available with the full text of this article at NEJM.org, as is the Supplementary 
Appendix, which provides lists of trial committees, sites, and investigators. Details regarding 
the trial rationale, design, and methods have been described previously.13
An executive committee was responsible for the design, interpretation, and supervision of 
the trial, including the development of the protocol and protocol amendments. The trial was 
sponsored by the National Institute of Neurological Disorders and Stroke (NINDS). Sanofi 
provided the clopidogrel and matching placebo for 75% of the patients enrolled in the trial 
and provided comments on an earlier version of the manuscript. There was no other industry 
involvement in the trial and no confidentiality agreement between the authors and Sanofi. 
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The authors vouch for the accuracy and completeness of the data and reporting of adverse 
events and for the adherence of the trial to the protocol.
An independent data and safety monitoring board provided recommendations to NINDS and 
guidance to the executive committee, along with monthly assessments of safety and study 
conduct and oversight of the interim analyses. The members of an independent clinical-event 
committee who were unaware of group assignments adjudicated primary and secondary 
efficacy outcomes and major and minor bleeding events.
TRIAL POPULATION
Patients who were at least 18 years of age were enrolled if they could undergo 
randomization within 12 hours after having an acute ischemic stroke with a score of 3 or less 
on the National Institutes of Health Stroke Scale (NIHSS) (scores range from 0 to 42, with 
higher scores indicating greater stroke severity) or a high-risk TIA with a score of 4 or more 
on the ABCD2 scale14 (which estimates the risk of recurrent stroke after a TIA on the basis 
of age, blood pressure, clinical features, duration of symptoms, and presence of diabetes; 
scores ranges from 0 to 7, with higher scores indicating a greater risk of stroke). They were 
also required to undergo computed tomography or magnetic resonance imaging to rule out 
intracranial bleeding or other conditions that could explain the neurologic symptoms or 
detect any contraindications to a trial treatment. Patients with TIA and minor, nondisabling 
ischemic stroke are generally not considered to be candidates for thrombolysis or 
endovascular therapy.10 Additional details regarding the inclusion and exclusion criteria are 
provided in the protocol.13
Patients were ineligible if the symptoms of the initial TIA were limited to isolated 
numbness, isolated visual changes, or isolated dizziness or vertigo or if they had received 
any thrombolytic therapy within 1 week before the event. Patients were also ineligible if 
they were candidates for thrombolysis, endovascular therapy, or endarterectomy; had 
planned use of antiplatelet therapy or anticoagulation therapy (including those with 
presumed atrial fibrillation or cardiovascular disease, in whom anticoagulation would be 
indicated); had a contraindication to aspirin or clopidogrel; or had anticipated use of a 
nonsteroidal antiinflammatory drug for more than 7 days during the trial period. Written 
informed consent was required before the performance of any trial procedure.
TRIAL TREAMENTS
Patients were randomly assigned in a 1:1 ratio to receive either clopidogrel plus aspirin or 
placebo plus aspirin, with stratification according to trial site, with the use of an interactive 
Web-based system. Patients in the group receiving clopidogrel plus aspirin were given a 
600-mg loading dose of clopidogrel, followed by 75 mg per day from day 2 to day 90, and a 
dose of open-label aspirin that ranged from 50 mg to 325 mg per day. Patients in the aspirin-
only group received placebo that matched the appearance and taste of the clopidogrel tablets 
and the same range of aspirin doses. In the two groups, the dose of aspirin was selected by 
the treating physician. A dose of 162 mg daily for 5 days followed by 81 mg daily was 
recommended, consistent with guidelines.6,10 The first dose of trial medication was to be 
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given as soon after randomization as possible. Patients were to be followed for 90 days (with 
a window of ±14 days) after randomization.
OUTCOMES
The primary outcome was the risk of a composite of ischemic stroke, myocardial infarction, 
or death from ischemic vascular causes (major ischemic events) on the basis of standard 
definitions.13 The primary safety outcome was the risk of major hemorrhage, which was 
defined as symptomatic intracranial hemorrhage, intraocular bleeding causing vision loss, 
transfusion of 2 or more units of red cells or an equivalent amount of whole blood, 
hospitalization or prolongation of an existing hospitalization, or death due to hemorrhage.
15,16
Key secondary efficacy end points were each component of the primary efficacy outcome, a 
composite of the primary efficacy outcome and major hemorrhage, and the total number of 
ischemic and hemorrhagic strokes. Secondary safety outcomes included hemorrhagic stroke, 
symptomatic intracerebral hemorrhage, other symptomatic intracranial hemorrhage, major 
hemorrhage other than intracranial hemorrhage, minor hemorrhage that included 
asymptomatic intracranial hemorrhage, and death from any cause.13 Additional prespecified 
secondary and tertiary outcomes are provided in the statistical analysis plan in the 
Supplementary Appendix.
STASTISTICAL ANALYSIS
We determined that a sample of 4150 patients would provide the trial with a power of 90% 
to detect a hazard ratio of 0.75 with a two-sided alpha level of 0.05 on the basis of an event 
rate of 15% in the aspirin-only group. The sample was inflated to account for two interim 
analyses of the primary efficacy outcome with the use of an O’Brien–Fleming spending 
function. The spending-function approach allowed for additional efficacy interim analyses to 
be conducted at the request of the data and safety monitoring board while maintaining the 
type I error rate. On the basis of the observed event rate in the aspirin-only group at the first 
interim analysis, the sample was increased to 5840 patients to provide the trial with a power 
of 80% with other variables remaining unchanged in the calculation.
We performed the analyses according to the intention-to-treat principle, using adjudicated 
outcomes and data from all the patients who had undergone randomization. Data for patients 
who did not have a 90-day assessment were censored on the 7-day assessment date, on the 
date of an event, or on the date of death, whichever came later. We performed a secondary, 
as-treated analysis of the primary outcome that included patients who had received at least 
one dose of a trial regimen, with data censored 1 day after permanent discontinuation of trial 
medication.
We used the log-rank test to compare the time from randomization to the first occurrence of 
any given end point and a Cox proportionalhazards model to estimate the hazard ratio and 
95% confidence intervals. There was no adjustment for baseline covariates or for the aspirin 
dose in the primary efficacy or safety analyses. Interactions between treatment assignment 
and prespecified subgroups were evaluated in the Cox model. A P value for interaction of 
less than 0.05 was considered to indicate statistical significance. We used a Cox model 
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stratified according to time point to perform a secondary analysis of the primary efficacy and 
primary safety outcomes comparing the treatment effect during four time periods: days 0 to 
7 versus days 8 to 90 and days 0 to 30 versus days 31 to 90. Secondary efficacy outcome 
analyses were not adjusted for multiple comparisons and are considered to be exploratory. A 
post hoc Bonferroni calculation was made for reference purposes to derive an adjusted 
threshold for P values to account for multiple comparisons of secondary outcomes.
RESULTS
Trial Discontinuation
In August 2017, the prespecified boundary for a safety signal of major hemorrhage was 
exceeded. Because of the small number of patients with hemorrhage, it was decided to 
follow these events until a planned meeting of the data and safety monitoring board in 
December 2017. At that meeting, the board recommended halting enrollment to the trial 
because of confirmation of a significant excess in the number of patients with major 
hemorrhage in the combined antiplatelet group, and a planned analysis determined that a 
treatment effect had crossed the significance boundary for efficacy. A summary of the 
board’s decision to halt the trial early is provided in the Supplementary Appendix.
PATIENTS
At the time that the trial was halted, 4881 patients had been enrolled, which represented 
83.6% of the anticipated number of patients. Of these patients, 4782 (98.0%) had been 
followed for at least 7 days, and 4557 (93.4%) had completed the 90-day trial visit or had 
died (Fig. 1). Discontinuation of a trial medication occurred in 29.6% of the patients in the 
group receiving clopidogrel plus aspirin and in 27.5% of those receiving aspirin alone; rates 
of withdrawal from the trial or loss to follow-up were 6.4% in the group receiving 
clopidogrel plus aspirin and 6.8% in the aspirin group. There were no significant differences 
in the baseline characteristics between the two groups (Table 1, and Table S5 in the 
Supplementary Appendix).
Primary and Secondary Efficacy Outcomes
The composite primary efficacy outcome occurred in 121 patients (5.0%) receiving 
clopidogrel plus aspirin and in 160 patients (6.5%) receiving aspirin alone (hazard ratio, 
0.75; 95% confidence interval [CI], 0.59 to 0.95; P = 0.02) (Table 2 and Fig. 2A). The 
secondary outcome of ischemic stroke occurred in 112 patients (4.6%) receiving clopidogrel 
plus aspirin and in 155 patients (6.3%) receiving aspirin alone (hazard ratio, 0.72; 95% CI, 
0.56 to 0.92; P = 0.01). Except for stroke, there were no significant differences between 
treatment groups in the other components of the composite primary efficacy outcome (Table 
2). The risk of total ischemic or hemorrhagic stroke was lower with clopidogrel plus aspirin 
than with aspirin alone (hazard ratio, 0.74; 95% CI, 0.58 to 0.94; P = 0.01). A post hoc 
Bonferroni-corrected P value that incorporates five main secondary outcome comparisons is 
shown in Table 2 for reference.
There were no significant treatment-by-subgroup interactions in prespecified subgroups, but 
the number of patients with available data for analysis limited the power to determine 
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interactions (Fig. 3). There was no difference in treatment effect according to the 
predominant daily aspirin dose received during the trial period.
The proportional-hazard assumption of the treatment effect over a period of 90 days did not 
hold for the primary efficacy outcome. In a secondary analysis of the treatment effect 
according to time period, the benefit of clopidogrel plus aspirin was greater in the first 7 
days and in the first 30 days than at 90 days (P = 0.04 for days 0 to 7 and P = 0.02 for days 0 
to 30), whereas the risk of hemorrhage with clopidogrel plus aspirin versus aspirin alone was 
greater during the period from 8 to 90 days than during the first 7 days (P = 0.04 for days 8 
to 90 and P = 0.34 for days 0 to 7) (Table S4 in the Supplementary Appendix).
The outcome of ischemic stroke, myocardial infarction, death from ischemic vascular 
causes, or major hemorrhage occurred in 141 patients (5.8%) receiving clopidogrel plus 
aspirin and in 167 patients (6.8%) receiving aspirin alone (hazard ratio, 0.84; 95% CI, 0.67 
to 1.05; P = 0.13). Additional secondary and tertiary analyses are shown in Table S6 in the 
Supplementary Appendix.
PRIMARY AND SECONDARY SAFETY OUTCOMES
The primary safety outcome of major hemorrhage occurred in 23 of 2432 patients (0.9%) 
receiving clopidogrel plus aspirin and in 10 of 2449 patients (0.4%) receiving aspirin alone 
(hazard ratio, 2.32; 95% CI, 1.10 to 4.87; P = 0.02) (Table 2 and Fig. 2B). In analyses of 
secondary safety outcomes, there were no significant differences between groups in the rates 
of hemorrhagic stroke, symptomatic intracerebral hemorrhage, or other symptomatic 
intracranial hemorrhage considered separately (Table 2). Death from hemorrhagic vascular 
causes occurred in 3 patients receiving clopidogrel plus aspirin and in 2 patients receiving 
aspirin alone (0.1% in each group). Nonfatal, nonintracranial hemorrhage accounted for 
most of the major hemorrhages (16 in patients receiving clopidogrel plus aspirin and 7 in 
those receiving aspirin alone). Minor hemorrhage occurred in 40 patients (1.6%) receiving 
clopidogrel plus aspirin and in 13 (0.5%) receiving aspirin alone (hazard ratio, 3.12; 95% CI, 
1.67 to 5.83; P = 0.002).
Serious adverse events other than components of the primary efficacy outcome were similar 
in the two groups, except that more patients receiving clopidogrel plus aspirin had events 
included in the Medical Dictionary for Regulatory Activities, version 15, coding designation 
“general disorders and administration-site conditions” (e.g., fever, fatigue, and edema) than 
those receiving aspirin alone (19 vs. 5, P = 0.004) (Tables S1 and S2 in the Supplementary 
Appendix). Reasons for early discontinuation of a trial drug are provided in Table S3 in the 
Supplementary Appendix.
AS-TREATED ANALYSES
In the as-treated analysis, major ischemic events occurred in 102 of 2398 patients (4.3%) 
treated with clopidogrel plus aspirin and in 141 of 2421 patients (5.8%) treated with aspirin 
alone (hazard ratio, 0.73; 95% CI, 0.56 to 0.94; P = 0.01). Major hemorrhage occurred in 21 
patients (0.9%) treated with clopidogrel plus aspirin and in 6 patients (0.2%) treated with 
aspirin alone (hazard ratio, 3.57; 95% CI, 1.44 to 8.85; P = 0.003). Data regarding outcomes 
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and adverse events in the as-treated population are provided in Tables S2 and S6 in the 
Supplementary Appendix.
DISSCUSSION
In this international, multicenter, randomized trial, we found that patients with minor 
ischemic stroke or high-risk TIA who received a combination of clopidogrel and aspirin had 
a lower risk of major ischemic events but a higher risk of major and minor hemorrhage than 
did those receiving aspirin alone. Ischemic stroke accounted for most of the composite 
events of the primary efficacy outcome, and the effect of dual antiplatelet treatment was 
attributable to a reduction in the rate of these strokes. It is not possible to make direct 
comparisons between clinical and safety outcomes because disability due to each of the 
outcomes cannot be ascertained, but we estimate that for every 1000 patients who are treated 
with clopidogrel plus aspirin during a period of 90 days, such treatment would prevent 
approximately 15 ischemic events and would cause 5 major hemorrhages.
The results of our trial broaden the results of the CHANCE trial involving Chinese patients 
to more diverse populations and care settings.12 In the CHANCE trial, there was a rate of 
moderate-to-severe bleeding of 0.3% in both the combined-antiplatelet group and the aspirin 
group. The results in the two trials apply to patients with stroke who were not appropriate 
candidates for anticoagulation, which thereby excluded those with stroke caused by 
presumed cardioembolism and those who were not candidates for treatment by intravenous 
thrombolysis or endovascular thrombectomy because their strokes were too mild to justify 
the use of these two treatments. The CHANCE trial tested a different combination of 
clopidogrel and aspirin than was used in our trial (two medications combined for the first 21 
days, followed by clopidogrel alone with an initial loading dose of 300 mg, as compared 
with 600 mg of clopidogrel, followed by 75 mg per day, for the duration of our trial).12 The 
smaller loading dose or limited duration of combined clopidogrel plus aspirin may have 
reduced the risk of hemorrhage in the CHANCE trial, a hypothesis that is consistent with 
our finding that the benefit of clopidogrel plus aspirin was concentrated in the first month of 
the trial, whereas the risk of hemorrhage remained relatively constant throughout the trial. In 
addition, polymorphisms in the gene encoding CYP2C19 that are associated with 
incomplete metabolism of clopidogrel into its active form are common among persons of 
Asian ancestry.17
The international SOCRATES (Acute Stroke or Transient Ischemic Attack Treated with 
Aspirin or Ticagrelor and Patient Outcomes) trial compared ticagrelor, a P2Y12 inhibitor, 
with aspirin in an international population and found no between-group difference in the risk 
of major vascular events.18 The combination of ticagrelor and aspirin is being tested in the 
THALES (Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA 
[acetylsalicylic acid] for Prevention of Stroke and Death) trial (ClinicalTrials .gov number, 
NCT03354429). Blockade of platelet activity beyond what is achieved by clopidogrel and 
aspirin may lead to excess hemorrhage. In the TARDIS (Triple Antiplatelets for Reducing 
Dependency after Ischemic Stroke) trial, investigators compared a combination of 
clopidogrel, aspirin, and dipyridamole with either clopidogrel alone or aspirin plus 
dipyridamole administered within 48 hours after the onset of ischemic stroke or TIA.19 They 
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found that patients who received the triple combination had no benefit with regard to the 
incidence and severity of recurrent stroke but had a higher rate of hemorrhage than those 
who received fewer medications.
Our trial has limitations. Patients with moderate-to-severe stroke, those with cardioembolic 
stroke, and those who are candidates for thrombolysis or thrombectomy were not 
represented in the trial, so results cannot be generalized to these groups. Entry criteria also 
resulted in a limited number of patients with symptomatic carotid atherosclerosis, a group 
that may benefit from platelet inhibition.20 A trial drug was discontinued permanently in 
29% of the patients before trial follow-up was complete. However, rates of discontinuation 
were similar in the two treatment groups, and reasons for discontinuation were similar. 
Furthermore, most outcome events occurred early, before the majority of the 
discontinuations had occurred, and results in an as-treated analysis were similar to those in 
the intentionto-treat analysis. The overall event rates in our trial were lower than expected,
1–4 particularly among the patients in the TIA group who had low ABCD2 scores, which 
suggests that some patients may not have had a TIA and would have been unlikely to benefit 
from treatment. The aspirin dose varied in the two treatment groups, which reflected the 
clinical practices of local investigators; however, in a potentially underpowered analysis, no 
difference in treatment effect was shown across aspirin doses.
In conclusion, in patients from diverse countries with minor ischemic stroke or high-risk 
TIA, those who received a combination of clopidogrel and aspirin had a lower risk of a 
composite of ischemic stroke, myocardial infarction, or death from ischemic vascular causes 
but had a higher risk of major hemorrhage than patients who received aspirin alone during 
the 90-day trial period.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Enrollment and Outcomes (Intention-to-Treat Analysis).
Patients who discontinued a trial drug were included in the intention-to-treat analysis, as 
were patients who withdrew consent or were lost to follow-up. In the as-treated analysis, 
data for patients who received a trial drug were censored at the time of discontinuation.
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Figure 2. Primary Efficacy and Safety Outcomes.
Shown are the percentages of patients with the primary efficacy outcome (a composite of 
ischemic stroke, myocardial infarction, or death from ischemic vascular causes) (Panel A) 
and the primary safety outcome of major hemorrhage (Panel B). Inset graphs show the same 
data on an expanded y axis.
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Figure 3. Primary Efficacy Outcome, According to Predefined Subgroup.
Race was determined by the investigator. Among patients with ischemic stroke, the 
qualifying score for participation in the trial was 3 or less on the National Institutes of 
Health Stroke Scale (NIHSS), which ranges from 0 to 42, with higher scores indicating 
greater stroke severity. The NIHSS score was missing at baseline for 23 patients, and 6 
patients had an NIHSS score above 3 and were excluded from the subgroup analysis of 
NIHSS score (score of 0 or 1 vs. score of 2 or 3). Among patients with transient ischemic 
attack (TIA), the qualifying score was 4 or more on the ABCD2 scale, which is used to 
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estimate the risk of recurrent stroke on the basis of age, blood pressure, clinical features, 
duration of symptoms, and presence of diabetes, with scores ranging from 0 to 7, with 
higher scores indicating a greater risk of stroke. CT denotes computed tomography, and MRI 
magnetic resonance imaging.
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